Author(s) Stephen Appezzato
Live from Asembia AXS26, Austin Russian examines how specialty therapy launches are evolving.
In part two of Pharmaceutical Commerce’s conversation with Austin Russian, SVP of Program Excellence at PANTHERx Rare, conducted live at Asembia AXS26, he discusses the advantages and challenges of manufacturers taking a more active role in the patient journey, as well as how rare disease and cell and gene therapy launches are evolving.